NASDAQ$LYEL
Lyell Immunopharma Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Lyell Immunopharma reported Q4 2024 a net loss of $191.9M.
For Q4 2024, Lyell Immunopharma reported net loss was $191.9M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $191.9M.
- MD&A highlights operating priorities, liquidity, and sector risks.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Lyell Immunopharma · Revenue · Quarterly
$11
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.
Tailwinds
- Pipeline progress and partnership economics.
- Cash supports near-term operating plans.
Headwinds
- Operating losses until commercial scale.
- Financing and trial outcomes affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.5%
Avg return
Earnings day
-4.0%
Avg return
5 days after
+1.1%
Avg return
30 days after
73%
16 / 22 earnings
Positive
+20.3%
Q4 2024
Best reaction
-18.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.1% | -7.0% | -42.1% | |
| Q4 2025 | +2.5% | -19.0% | -9.6% | |
| Q3 2025 | -1.3% | +1.7% | +95.5% | |
| Q1 2025 | +4.6% | +2.0% | +21.1% | |
| Q4 2024 | +20.3% | +15.5% | -10.3% | |
| Q3 2024 | -17.6% | -21.3% | -38.9% | |
| Q2 2024 | +1.4% | -8.1% | -20.9% | |
| Q1 2024 | +7.6% | +4.2% | +13.6% | |
| Q4 2023 | +2.5% | -8.6% | -21.8% | |
| Q3 2023 | +6.8% | -24.8% | -11.8% | |
| Q2 2023 | +1.5% | -1.9% | -16.8% | |
| Q1 2023 | +6.9% | +6.5% | +50.9% | |
| Q4 2022 | +9.6% | +1.4% | -1.8% | |
| Q3 2022 | -18.3% | -17.0% | -28.8% | |
| Q2 2022 | +16.3% | +20.2% | +10.1% | |
| Q1 2021 | -12.4% | -22.8% | +1.5% | |
| Q1 2022 | -12.4% | -22.8% | +1.5% | |
| Q4 2019 | +6.1% | +6.1% | +1.6% | |
| Q4 2021 | +6.1% | +6.1% | +1.6% | |
| Q3 2021 | -4.1% | -3.6% | -18.8% | |
| Q4 2020 | +2.8% | +2.2% | +24.6% | |
| Q2 2021 | +2.8% | +2.2% | +24.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro